(Press-News.org) (Singapore – 10:05 a.m. SGT--September 11, 2023) – Osimertinib plus chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit compared to osimertinib alone, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
The FLAURA2 study was led by Dr. Pasi A. Jänne from the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute in Boston, Mass.
Osimertinib, a potent third-generation EGFR-TKI with central nervous system activity, has garnered attention for its targeted inhibition of both sensitizing and resistance EGFR mutations. According to Dr. Jänne, The FLAURA2 trial builds on the favorable results observed in the phase III FLAURA trial, where osimertinib displayed superiority over comparator EGFR-TKIs.
The study enrolled 557 patients and randomized them 1:1 into two treatment arms: osimertinib plus chemotherapy or osimertinib monotherapy. The combination arm involved a regimen of osimertinib (80 mg daily) alongside pemetrexed and either cisplatin or carboplatin.
“Results from the study demonstrated a remarkable improvement in progression-free survival (PFS) with the osimertinib plus chemotherapy approach, showcasing a statistically significant reduction in disease progression risk compared to osimertinib monotherapy,” Dr. Jänne said.
The data showed a compelling hazard ratio of 0.62 (95% CI 0.49, 0.79; p<0.0001) for progression-free survival, signifying an 8.8-month enhancement in median progression-free survival. Moreover, the objective response rate per investigator was notably higher in the combination arm at 83%, compared to 76% in the osimertinib monotherapy group. Safety analyses revealed that the combination therapy was generally well-tolerated, with manageable adverse events.
“These findings mark a significant advancement in the management of advanced EGFR-mutated NSCLC,” Dr. Jänne reported. “The FLAURA2 study supports osimertinib combined with platinum-pemetrexed chemotherapy as a new and promising first-line treatment option, poised to make a profound impact on patient outcomes in this challenging disease setting.”
About IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information.
About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration, and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2023.iaslc.org.
END
FLAURA2 results demonstrate osimertinib plus chemotherapy superior compared to osimertinib alone
2023-09-11
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
MARS trial: decortication and chemotherapy associated with worse outcomes for patients with resectable mesothelioma
2023-09-11
(Singapore, September 11, 2023, 10:05 a.m. SGT) – Extended pleurectomy decortication combined with chemotherapy is associated with worse survival outcomes, a higher incidence of serious adverse events, and a diminished quality of life compared to platinum and pemetrexed chemotherapy alone, according to research presented today the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
The UK Multicentre Randomised Trial, known as MARS 2, conducted by a team led by Professor Eric ...
Large-scale investigation supports modified classification system for pulmonary adenocarcinomas
2023-09-11
(Singapore – 10:05 a.m. SGT--September 11, 2023) – A modified adenocarcinoma classification approach significantly enhances reproducibility and may be an improvement on the existing World Health Organization classification system, according to research unveiled at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
The study, led by Dr. Erik Thunnissen, Department of Pathology, Amsterdam UMC, VU Medical Center, Amsterdam, The Netherlands, ...
Taiwan launches National Lung Cancer Early Detection Program detects 85 percent of lung cancer cases at early phase
2023-09-11
First-ever National Screening Program to Consider Family History
(Singapore – 10:05 a.m. SGT--September 11, 2023) – The Taiwan National Lung Cancer Early Detection Program detected 85 percent of lung cancer cases at either a phase 0 or phase 1 level, demonstrating that lung cancer screening can detect lung cancer at an early enough phase to allow doctors to intervene more effectively.
The results of the program were presented by Pan-Chyr Yang, MD, PhD from the National Taiwan University Hospital, at the International Association for the Study of Lung Cancer 2023 World Conference ...
Surgical outcomes of perioperative durvalumab in AEGEAN study to be presented at IASLC 2023 World Conference on Lung Cancer
2023-09-11
[Singapore, 10:05 a.m. SGT--September 11, 2023] – Adding perioperative durvalumab to neoadjuvant chemotherapy did not adversely impact surgery in patients with resectable NSCLC and was associated with a tolerable surgical safety profile, according to research presented today from the phase 3 AEGEAN trial at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer in Singapore.
"The AEGEAN trial demonstrated a clinically meaningful improvement in EFS ...
Treatment for dangerous snoring prevents deaths from heart disease
2023-09-11
Milan, Italy: People suffering with obstructive sleep apnoea (OSA) can reduce their risk of dying from cardiovascular disease if they use a continuous positive airway pressure (CPAP) machine at night, according to research presented at the European Respiratory Society International Congress in Milan, Italy [1].
CPAP may also work better than a weight loss drug in reducing the build-up of plaque in the arteries around the heart, according to a pilot study also presented at the European Respiratory Society International Congress [2].
People with OSA often snore loudly, their breathing starts and stops during the night, and they may ...
City living raises the risk of respiratory infections in babies and young children
2023-09-11
Milan, Italy: Young children growing up in towns and cities suffer from more respiratory infections than those who grow up in the countryside, according to research presented at the European Respiratory Society International Congress in Milan, Italy [1].
A second study, presented at the Congress and published in Pediatric Pulmonology today (Monday) [2], shows that factors such as attending day care, living in a damp home or near dense traffic increase the risk of chest infections in young children, while breastfeeding reduces the risk.
Researchers say that some children, who are otherwise healthy, can suffer with repeated infections, so it is important to understand why ...
Healthy guts containing diverse and mature bacteria are linked to less allergy-related wheezing and asthma in early childhood
2023-09-10
Milan, Italy: Babies and young children with more mature communities of bacteria present in their gut are less likely to develop allergy-related wheezing or asthma, according to research presented at the European Respiratory Society International Congress in Milan, Italy [1].
These communities of bacteria, known as microbiota, develop in the human body during the early years of life and are involved in processes that are helpful to the body, such as synthesising vitamins and boosting the immune system, or occasionally unhelpful, such as the role they play ...
Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension
2023-09-10
About The Study: Among individuals with uncontrolled hypertension in this randomized clinical trial that included 200 participants, use of lorundrostat was effective at lowering blood pressure compared with placebo, which will require further confirmatory studies.
Authors: Steven E. Nissen, M.D., of the Cleveland Clinic Foundation, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.16029)
Editor’s Note: Please see the article for additional ...
Benmelstobart plus anlotinib and chemotherapy shows benefit for patients with extensive-stage small-cell lung cancer
2023-09-10
[Singapore -- 10:35 a.m. SGT--September 10, 2023] - The combination of benmelstobart, anlotinib, and chemotherapy demonstrated significant benefits compared to placebo and chemotherapy in terms of median progression-free survival and overall survival for patients with extensive-stage small-cell lung cancer.
The research was presented today at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer in Singapore.
Extensive-stage small-cell lung cancer is a challenging malignancy to treat, ...
Exhaled breath analysis shows promise in detecting malignant pleural mesothelioma
2023-09-10
[Singapore -- 10:35 a.m. SGT--September 10, 2023] -- Identifying and analyzing volatile organic compounds in exhaled breath of patients with malignant pleural mesothelioma showed promise as a screening method for MPM, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Malignant pleural mesothelioma (MPM) is a challenging disease with limited treatment options and a poor prognosis. To improve ...